Background: The enduring presence of COVID-19 and subsequent increasing incidence of COVID-19 reinfection has prompted evaluation of associated risk factors, particularly the role of immunosuppression.
Objective: The objective of this study was to characterize cases indicative of COVID-19 reinfection with respect to their reported use of immunosuppressant/immunomodulating agents.
Methods: This cross-sectional observational study leveraged the Pfizer global safety database (SDB) containing adverse event data collected in association with use of Pfizer products between 1 October 2019, and 30 June 2022. Selected Medical Dictionary for Drug Regulatory Activities (MedDRA) Preferred Terms were used to identify COVID-19 cases; the search was further refined to comprise cases that subsequently reported events potentially indicative of COVID-19 reinfection.
Results: Of the cumulative total of 218,242 COVID-19 cases reported into the SDB, 4590 cases (2.1%) involving potential COVID-19 reinfection were identified. Of these 4590 cases of potential Covid-19 reinfection, a total of 134 cases reported COVID-19 specifically during treatment with pharmaceutical products, of which approximately 16% (21/134) of cases reported use of immunosuppressant/immunomodulating agents. Likewise, in the overall dataset (213,652 cases; excluding the 4590 cases involving potential COVID-19 recurrence), the percentage of reported immunosuppressant/immunomodulating agents was low (12%). In applying similar parameters to a dataset that excludes COVID-19 vaccine cases, 18% of cases reported use of immunosuppressant/immunomodulating agents (similar to the aforementioned 16% of cases reported from the overall total dataset that was inclusive of vaccine cases).
Conclusion: This pharmacovigilance study provides a characterization of cases indicative of COVID-19 reinfection with respect to reported use of immunosuppressant/immunomodulating agents. The observations generated from this cross-sectional observational analysis may prompt further research into the role of immunosuppression in COVID-19 reinfection, in an effort to better inform clinical practice and patient management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470511 | PMC |
| http://dx.doi.org/10.1007/s40261-022-01200-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COVID-19 reinfection in pregnancy: assessment of Severity and pregnancy outcomes in England.
J Infect
December 2024
UK Health Security Agency, London, United Kingdom.
Background: Disease severity and pregnancy outcomes following SARS-CoV-2 reinfections in pregnancy are not well understood.
Methods: We linked women aged 18 to 50 years testing positive in the community for COVID-19 between April 2021 and March 2022 to hospital, vaccine and maternal services databases. We compared hospital and intensive care unit (ICU) admission rates following infection and reinfection in pregnant and non-pregnant women, and low birthweight, prematurity and stillbirth in women infected and reinfected during pregnancy.
Predicting higher risk factors for COVID-19 short-term reinfection in patients with rheumatic diseases: a modeling study based on XGBoost algorithm.
J Transl Med
December 2024
Department of Rheumatology and Immunology, Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Tianhe District, Guangzhou, China.
Background: Corona virus disease 2019 (COVID-19) reinfection, particularly short-term reinfection, poses challenges to the management of rheumatic diseases and may increase adverse clinical outcomes. This study aims to develop machine learning models to predict and identify the risk of short-term COVID-19 reinfection in patients with rheumatic diseases.
Methods: We developed four prediction models using explainable machine learning to assess the risk of short-term COVID-19 reinfection in 543 patients with rheumatic diseases.
Unraveling the fear of COVID-19 reinfection: insights from frontline doctors in China.
Psychol Health Med
December 2024
Department of Emergency, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan, China.
Considering the end of global emergency status of Coronavirus-19 (COVID-19) and the persistent risk of reinfection for healthcare workers (HCWs), it is important to evaluate the attitude of the HCWs toward reinfecting with COVID-19. To gather information about participants' concerns regarding reinfection with COVID-19, a comprehensive online questionnaire was administered to all individuals involved in the study. DASS-21 was used to assess their mental health.
View Article and Find Full Text PDFThe Mental Burden of the COVID-19 Pandemic: A Retrospective Post-pandemic View From a Romanian Sample.
Cureus
October 2024
Faculty of Medicine, 'Ovidius' University, Constanta, ROU.
Background: The enduring psychological effects of the COVID-19 pandemic continue to affect individuals long after the immediate health concerns have subsided. This research aims to identify specific groups within the Romanian population who are at a higher risk of experiencing mental health challenges that can interfere with everyday life and may lead to more serious mental health disorders.
Methods: Conducted as a cross-sectional survey, this study assessed the severity of psychological distress using the Depression, Anxiety, and Stress Scale-21 (DASS-21) questionnaire in relation to COVID-19-related information and socio-demographic data to investigate the factors associated with psychological distress during the COVID-19 pandemic in Romania.
Prevalence and Risk Factors of COVID-19 Reinfection in Patients with Rheumatoid Arthritis: A Retrospective Observational Study.
Yonsei Med J
November 2024
Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Article Synopsis
- The study aimed to determine how common COVID-19 reinfection is among patients with rheumatoid arthritis (RA) and what risk factors contribute to it.
- Researchers analyzed data from 351 RA patients who had COVID-19, finding that 12.3% experienced reinfection over an average follow-up of 1.5 years, with leflunomide use significantly linked to a higher reinfection risk.
- Despite the reinfection occurrences, there were no notable changes in disease activity scores before and after reinfection, indicating overall stability in RA conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!